Hereditary Breast and Ovarian Cancer Syndrome

2

Review clinical trials related to Hereditary Breast and Ovarian Cancer Syndrome. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.

Participants needed: 80
Trial details
Age: 18-74Biological sex: FemaleType: InterventionalSponsor: Georgetown UniversityUpdated: Sep 30, 2025Locations: 1
Eligibility criteria

female [+6]

aged <18 or ≥75 [+1]

Status: Recruiting

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Ovarian cancer is the gynecological malignancy with the highest fatality rate, seriously threatening the life and health of women. One of the main reasons for its high fatality rate is that approximately 70% of patients are diagnosed at an advanced stage. Fortunately, about 1/5 of ovarian cancers are associated with genetic factors, providing us with an opportunity to screen high-risk populations and thereby prevent and diagnose the disease at an early stage and reduce the disease burden. Currently, research related to hereditary ovarian cancer in China is still very scarce, and clinical practice relies on data from foreign studies. However, hereditary tumors have distinct regional and ethnic characteristics, making it urgent to conduct clinical research based on the Chinese population to guide clinical practice in China. Current research suggests that approximately 50% - 60% of hereditary ovarian cancers are closely related to the BRCA1/2 genes. Therefore, accurately assessing the risk of ovarian cancer in BRCA1/2 germline mutation carriers is of great significance for the prevention and treatment of hereditary ovarian cancer.

Participants needed: 10,000
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Peking University Third HospitalUpdated: Jun 26, 2025Locations: 1
Eligibility criteria

Pathologically diagnosed with ovarian malignant tumor. [+2]

① Patients who refuse to provide necessary information.